Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pamvatamig + ensartinib
- Development stage
- Phase 2
- Lead developer
- Merus
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
MCLA-129 + Bemena (pamvatamig + ensartinib) is a combination therapy under clinical development for the treatment of advanced solid tumors, particularly non-small cell lung cancer (NSCLC). Pamvatamig (MCLA-129) is a humanized bispecific monoclonal antibody targeting epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (c-MET), designed to block oncogenic signaling and overcome resistance mediated by c-MET upregulation. Ensartinib (Bemena) is an orally bioavailable, small-molecule tyrosine kinase inhibitor (TKI) that potently inhibits anaplastic lymphoma kinase (ALK) as well as other kinases such as c-MET, ROS1, and EphA2. The combination is being evaluated in Phase I/II clinical trials to assess its safety, tolerability, pharmacokinetics, and efficacy in patients with advanced solid tumors, leveraging dual inhibition of EGFR and c-MET/ALK pathways to combat resistance mechanisms in lung cancer.
- Brand names
- Gevalka
- Other names
- MCLA-129 + BemenaMCLA-129 + ensartinibMCLA129 + BemenaMCLA129 + ensartinibpamvatamig + Bemenapamvatamig + ensartinib
02
Targets
ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)EGFR (Epidermal growth factor receptor)MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on pamvatamig + ensartinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pamvatamig + ensartinib.